• 1. Slack J, Boston RC, Soma LR, et al. Occurrence of cardiac arrhythmias in Standardbred racehorses. Equine Vet J 2015;47:398404.

  • 2. Ohmura H, Hiraga A, Takahashi T, et al. Risk factors for atrial fibrillation during racing in slow-finishing horses. J Am Vet Med Assoc 2003;223:8488.

    • Search Google Scholar
    • Export Citation
  • 3. Reef VB, Reimer JM, Spencer PA. Treatment of atrial fibrillation in horses: new perspectives. J Vet Intern Med 1995;9:5767.

  • 4. Deem DA, Fregin GF. Atrial fibrillation in horses: a review of 106 clinical cases, with consideration of prevalence, clinical signs, and prognosis. J Am Vet Med Assoc 1982;180:261265.

    • Search Google Scholar
    • Export Citation
  • 5. Rose RJ, Davis PE. Treatment of atrial fibrillation in three racehorses. Equine Vet J 1977;9:6871.

  • 6. Muir WW III, Reed SM, McGuirk SM. Treatment of atrial fibrillation in horses by intravenous administration of quinidine. J Am Vet Med Assoc 1990;197:16071610.

    • Search Google Scholar
    • Export Citation
  • 7. Morris DD, Fregin GF. Atrial fibrillation in horses: factors associated with response to quinidine sulfate in 77 clinical cases. Cornell Vet 1982;72:339349.

    • Search Google Scholar
    • Export Citation
  • 8. De Clercq D, van Loon G, Tavernier R, et al. Use of propafenone for conversion of chronic atrial fibrillation in horses. Am J Vet Res 2009;70:223227.

    • Search Google Scholar
    • Export Citation
  • 9. McGurrin MKJ, Physick-Sheard PW, Kenney DG. How to perform transvenous electrical cardioversion in horses with atrial fibrillation. J Vet Cardiol 2005;7:109119.

    • Search Google Scholar
    • Export Citation
  • 10. McGurrin MKJ, Physick-Sheard PW, Kenney DG. Transvenous electrical cardioversion of equine atrial fibrillation: patient factors and clinical results in 72 treatment episodes. J Vet Intern Med 2008;22:609615.

    • Search Google Scholar
    • Export Citation
  • 11. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation 1989;80:10631069.

    • Search Google Scholar
    • Export Citation
  • 12. Glendinning SA. The use of quinidine sulphate for the treatment of atrial fibrillation in twelve horses. Vet Rec 1965;77:951960.

  • 13. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:6972.

    • Search Google Scholar
    • Export Citation
  • 14. Ohmura H, Hiraga A, Aida H, et al. Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. J Vet Med Sci 2001;63:511514.

    • Search Google Scholar
    • Export Citation
  • 15. Ohmura H, Nukada T, Mizuno Y, et al. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. J Vet Med Sci 2000;62:711715.

    • Search Google Scholar
    • Export Citation
  • 16. van Loon G, Blissitt KJ, Keen JA, et al. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. Equine Vet J 2004;36:609614.

    • Search Google Scholar
    • Export Citation
  • 17. Birettoni F, Porciello F, Rishniw M, et al. Treatment of chronic atrial fibrillation in the horse with flecainide: personal observation. Vet Res Commun 2007;31:273275.

    • Search Google Scholar
    • Export Citation
  • 18. Risberg ÅI, McGuirk SM. Successful conversion of equine atrial fibrillation using oral flecainide. J Vet Intern Med 2006;20:207209.

    • Search Google Scholar
    • Export Citation
  • 19. Reef VB, Bonagura J, Buhl R, et al. Recommendations for management of equine athletes with cardiovascular abnormalities. J Vet Intern Med 2014;28:749761.

    • Search Google Scholar
    • Export Citation
  • 20. Dembek KA, Hurcombe SDA, Schober KE, et al. Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate. J Vet Emerg Crit Care (San Antonio) 2014;24:759763.

    • Search Google Scholar
    • Export Citation
  • 21. Aliot E, Capucci A, Crijns HJ, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011;13:161173.

    • Search Google Scholar
    • Export Citation
  • 22. Reef VB, Levitan CW, Spencer PA. Factors affecting prognosis and conversion in equine atrial fibrillation. J Vet Intern Med 1988;2:16.

    • Search Google Scholar
    • Export Citation

Advertisement

Treatment of recent-onset atrial fibrillation with quinidine and flecainide in Thoroughbred racehorses: 107 cases (1987–2014)

Yuji Takahashi DVM1, Yuhiro Ishikawa DVM2, and Hajime Ohmura DVM, PhD3
View More View Less
  • 1 Racehorse Clinic, Ritto Training Center, Japan Racing Association, 1028 Misono, Ritto-shi, Shiga 520-3085, Japan.
  • | 2 Joban Branch, Equine Research Institute, Japan Racing Association, 71 Uenohara, Jobanshiratori-machi, Iwaki-shi, Fukushima 972-8325, Japan.
  • | 3 Sports Science Division, Equine Research Institute, Japan Racing Association, 321-4 Tokami-cho, Utsunomiya-shi, Tochigi 320-0856, Japan.

Abstract

OBJECTIVE To compare the efficacy of quinidine and flecainide in treating naturally occurring, recent-onset atrial fibrillation (AF) in Thoroughbred racehorses.

DESIGN Retrospective case series.

ANIMALS 107 Thoroughbred racehorses.

PROCEDURES Medical records of racehorses with AF that were treated with quinidine or flecainide between 1987 and 2014 were reviewed. Signalment, history, treatments, complications, and outcome data were collected. Horses were allocated to 2 groups according to the initial treatment: initial treatment with quinidine (group 1) or initial treatment with flecainide (group 2). Horses in group 2 that did not convert to sinus rhythm with flecainide were then administered quinidine (group 3). Complications, total quinidine dose, and duration of treatment were compared. Rates of conversion for horses treated with quinidine versus flecainide were also compared.

RESULTS Overall rate of cardioversion was 91% (97/107). There was a significant difference in the rate of cardioversion for quinidine alone (91% [71/78]), compared with flecainide alone (41% [12/29]). In group 3, the conversion rate after the addition of quinidine treatment was 82% (14/17). Total quinidine dose and treatment duration did not differ significantly between groups 1 and 3.

CONCLUSIONS AND CLINICAL RELEVANCE Overall rate of cardioversion for Thoroughbred racehorses with AF was similar to that in previous reports. Flecainide treatment was less effective than quinidine treatment, but the frequency of complications did not differ between quinidine and flecainide. Further investigation is suggested to evaluate the efficacy of flecainide for cardioversion in athletic horses.

Abstract

OBJECTIVE To compare the efficacy of quinidine and flecainide in treating naturally occurring, recent-onset atrial fibrillation (AF) in Thoroughbred racehorses.

DESIGN Retrospective case series.

ANIMALS 107 Thoroughbred racehorses.

PROCEDURES Medical records of racehorses with AF that were treated with quinidine or flecainide between 1987 and 2014 were reviewed. Signalment, history, treatments, complications, and outcome data were collected. Horses were allocated to 2 groups according to the initial treatment: initial treatment with quinidine (group 1) or initial treatment with flecainide (group 2). Horses in group 2 that did not convert to sinus rhythm with flecainide were then administered quinidine (group 3). Complications, total quinidine dose, and duration of treatment were compared. Rates of conversion for horses treated with quinidine versus flecainide were also compared.

RESULTS Overall rate of cardioversion was 91% (97/107). There was a significant difference in the rate of cardioversion for quinidine alone (91% [71/78]), compared with flecainide alone (41% [12/29]). In group 3, the conversion rate after the addition of quinidine treatment was 82% (14/17). Total quinidine dose and treatment duration did not differ significantly between groups 1 and 3.

CONCLUSIONS AND CLINICAL RELEVANCE Overall rate of cardioversion for Thoroughbred racehorses with AF was similar to that in previous reports. Flecainide treatment was less effective than quinidine treatment, but the frequency of complications did not differ between quinidine and flecainide. Further investigation is suggested to evaluate the efficacy of flecainide for cardioversion in athletic horses.

Contributor Notes

Drs. Takahashi and Ohmura's present address is Sports Science Division, Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke-shi, Tochigi 329-0412, Japan.

Address correspondence to Dr. Yuji Takahashi (yuji_takahashi@equinst.go.jp).